Watts, Gerald F. http://orcid.org/0000-0003-2276-1524
Gidding, Samuel S.
Hegele, Robert A. http://orcid.org/0000-0003-2861-5325
Raal, Frederick J. http://orcid.org/0000-0002-9170-7938
Sturm, Amy C.
Jones, Laney K. http://orcid.org/0000-0002-6182-5634
Sarkies, Mitchell N.
Al-Rasadi, Khalid
Blom, Dirk J. http://orcid.org/0000-0003-3965-5912
Daccord, Magdalena
de Ferranti, Sarah D.
Folco, Emanuela
Libby, Peter http://orcid.org/0000-0002-1502-502X
Mata, Pedro
Nawawi, Hapizah M.
Ramaswami, Uma http://orcid.org/0000-0002-4703-7447
Ray, Kausik K.
Stefanutti, Claudia http://orcid.org/0000-0003-3448-2426
Yamashita, Shizuya
Pang, Jing http://orcid.org/0000-0002-9700-6948
Thompson, Gilbert R. http://orcid.org/0000-0003-0023-4651
Santos, Raul D. http://orcid.org/0000-0002-9860-6582
Article History
Accepted: 12 May 2023
First Online: 15 June 2023
Competing interests
: The authors have received no financial support for the research, authorship and/or publication of this article. The pharmaceutical industry was not involved and did not contribute financially to the development of this guidance. G.F.W. has received honoraria related to consulting, research and/or speaker activities from Amgen, Arrowhead, AstraZeneca, CRISPR Therapeutics, Esperion, Novartis and Sanofi. S.S.G. is a consultant for Esperion and is on a scientific advisory panel for Silence Therapeutics. R.A.H. has received honoraria related to consulting, research and/or speaker activities from Acasti, Akcea-Ionis, Amgen, Arrowhead, HLS Therapeutics, Pfizer, Novartis and Sanofi/Regeneron. F.J.R. has received personal fees from Amgen, LIB Therapeutics, Novartis, Regeneron and Sanofi-Aventis. A.C.S. is an employee and stockholder of 23andMe, an adviser to Nest Genomics and a consultant on the NHLBI IMPACT-FH grant. L.K.J. is a consultant for Novartis. M.N.S. has received personal fees from Amgen. K.A.-R. has received grants and personal fees from Sanofi and personal fees from Abbott and Novartis. D.J.B. has received grants for clinical trials and/or personal fees from Abbott, Akcea, Amgen, Amryt, AstraZeneca, Ionis, LIB Therapeutics, Novartis, Sanofi and Silence Therapeutics. S.D.d.F. has received personal fees from UpToDate. P.L. has received research funding from Novartis; is on the Board of Directors of XBiotech; has a financial interest in Soley Therapeutics, TenSixteen Bio and XBiotech; is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer and Sanofi-Regeneron; is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Medimmune, Moderna, Novartis, Olatec Therapeutics, PlaqueTec, Soley Therapeutics, TenSixteen Bio and XBiotech. P.M. has received grants from Amgen and Sanofi. K.K.R. has received grants from Amgen, Daiichi Sankyo, Regeneron and Sanofi; personal fees for serving on steering committees, executive committees or advisory boards from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cargene, CRISPR Therapeutics, CSL Behring, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, New Amsterdam Pharma, Novartis, Novo Nordisk, Sanofi, Scribe, Silence Therapeutics and Vaxxinity; personal fees for CME and non-CME lectures from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, Sanofi and Viatris. C.S. has consulted and received research grants from Aegerion, Amgen, B. Braun Avitum, Cerenis Therapeutics, Difass, Fresenius Medical Care, Isis (Ionis) Pharmaceuticals, Kaneka NV, Kowa Company, Merck Sharp & Dohme, Regeneron-Sanofi and Ultragenyx. S.Y. has received personal fees from Amgen, Kowa Company, Merck Sharp & Dohme, Novartis and Otsuka Pharmaceutical Company. R.D.S. has received honoraria related to consulting, research and/or speaker activities from Abbott, Ache, Amgen, AstraZeneca, EMS, Esperion, GETZ Pharma, Kowa, Libbs, Novartis, Novo-Nordisk, Merck, Merck Sharp & Dohme, Pfizer, PTC Therapeutics and Sanofi/Regeneron. The other authors declare no competing interests.
Free to read: This content has been made available to all.